Literature DB >> 29770223

Profound hearing loss following surgery in pediatric patients with posterior fossa low-grade glioma.

Yahya Ghazwani1, Ibrahim Qaddoumi1, Johnnie K Bass2, Shengjie Wu3, Jason Chiang4, Frederick Boop5,6,7,8, Amar Gajjar1, Zsila Sadighi9.   

Abstract

BACKGROUND: Hearing loss may occur in patients with posterior fossa low-grade glioma who undergo surgery.
METHODS: We retrospectively reviewed 217 patients with posterior fossa low-grade glioma, including 115 for whom results of hearing tests performed after surgery and before chemotherapy or radiation therapy were available. We explored the association of UHL with age at diagnosis, sex, race, tumor location, extent of resection, posterior fossa syndrome, ventriculoperitoneal shunt placement, and histology.
RESULTS: Of the 115 patients, 15 (13.0%: 11 male, 6 black, 8 white, 1 multiracial; median age 7 years [range, 1.3-17.2 years]) had profound UHL after surgery alone or before receiving ototoxic therapy. Median age at tumor diagnosis was 6.8 years (range, 0.7-14.1 years), and median age at surgery was 6.8 years (range, 0.7-14.1 years). Patients with UHL had pathology characteristic of pilocytic astrocytoma (n = 10), ganglioglioma (n = 4), or low-grade astrocytoma (n = 1). Of these 15 patients, 4 underwent biopsy, 1 underwent gross total resection, 1 underwent near-total resection, and 9 underwent subtotal resection. UHL was more frequent in black patients than in white patients (OR 7.3, P = .007) and less frequent in patients who underwent gross total resection or near-total resection than in those who underwent subtotal resection (OR 0.11, P = .02).
CONCLUSIONS: Children undergoing surgery for posterior fossa low-grade glioma are at risk for UHL, which may be related to race or extent of resection. These patients should receive postoperative audiologic testing, as earlier intervention may improve outcomes.

Entities:  

Keywords:  hearing loss; low-grade glioma; pediatric; posterior fossa; surgery

Year:  2017        PMID: 29770223      PMCID: PMC5946892          DOI: 10.1093/nop/npx025

Source DB:  PubMed          Journal:  Neurooncol Pract        ISSN: 2054-2577


  68 in total

1.  Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem.

Authors:  Milind Ronghe; Darren Hargrave; Ute Bartels; Uri Tabori; Sucheta Vaidya; Chris Chandler; Abhaya Kulkarni; Eric Bouffet
Journal:  Pediatr Blood Cancer       Date:  2010-09       Impact factor: 3.167

2.  Sound localization acuity in children with unilateral hearing loss who wear a hearing aid in the impaired ear.

Authors:  Patti M Johnstone; Anna K Nábĕlek; Velma S Robertson
Journal:  J Am Acad Audiol       Date:  2010-09       Impact factor: 1.664

3.  Auditory complications in childhood cancer survivors: a report from the childhood cancer survivor study.

Authors:  Kimberly Whelan; Kayla Stratton; Toana Kawashima; Wendy Leisenring; Susan Hayashi; John Waterbor; Julie Blatt; Charles A Sklar; Roger Packer; Pauline Mitby; Leslie L Robison; Ann C Mertens
Journal:  Pediatr Blood Cancer       Date:  2011-02-15       Impact factor: 3.167

4.  Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.

Authors:  R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

5.  Long term outcome in surgically treated posterior fossa epidermoids.

Authors:  Chittur Viswanathan Gopalakrishnan; Khursheed A Ansari; Suresh Nair; Girish Menon
Journal:  Clin Neurol Neurosurg       Date:  2013-12-07       Impact factor: 1.876

6.  Cystic cerebellar astrocytomas in childhood.

Authors:  T W Griffin; D Beaufait; J C Blasko
Journal:  Cancer       Date:  1979-07       Impact factor: 6.860

7.  Benign cerebellar astrocytomas in children.

Authors:  P Pencalet; W Maixner; C Sainte-Rose; A Lellouch-Tubiana; G Cinalli; M Zerah; A Pierre-Kahn; E Hoppe-Hirsch; M Bourgeois; D Renier
Journal:  J Neurosurg       Date:  1999-02       Impact factor: 5.115

8.  Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas.

Authors:  Dennis J Kuo; Howard L Weiner; Jeffrey Wisoff; Douglas C Miller; Edmond A Knopp; Jonathan L Finlay
Journal:  J Pediatr Hematol Oncol       Date:  2003-05       Impact factor: 1.289

Review 9.  Pediatric low-grade gliomas and the need for new options for therapy: Why and how?

Authors:  Ibrahim Qaddoumi; Iyad Sultan; Alberto Broniscer
Journal:  Cancer Biol Ther       Date:  2009-01-22       Impact factor: 4.742

10.  Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database.

Authors:  Pratiti Bandopadhayay; Guillaume Bergthold; Wendy B London; Liliana C Goumnerova; Andres Morales La Madrid; Karen J Marcus; Dongjing Guo; Nicole J Ullrich; Nathan J Robison; Susan N Chi; Rameen Beroukhim; Mark W Kieran; Peter E Manley
Journal:  Pediatr Blood Cancer       Date:  2014-01-30       Impact factor: 3.167

View more
  1 in total

1.  Treatment burden and long-term health deficits of patients with low-grade gliomas or glioneuronal tumors diagnosed during the first year of life.

Authors:  Anthony P Y Liu; Camden Hastings; Shengjie Wu; Johnnie K Bass; Andrew M Heitzer; Jason Ashford; Robert Vestal; Mary E Hoehn; Yahya Ghazwani; Sahaja Acharya; Heather M Conklin; Frederick Boop; Thomas E Merchant; Amar Gajjar; Ibrahim Qaddoumi
Journal:  Cancer       Date:  2019-01-08       Impact factor: 6.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.